logo

For the Inventor, By the Inventor

Leuven, Belgium

Thrombogenics Nv

Calculating rank
USPTO Granted Patents = 21

% Expired Patents = 85.7



Trademarks = 1

Forward Citations = 82

Loading Chart...
Loading Chart...

16 inventors (with patents filed for the assignee):

goldMedal Marc De Smet (10 out of 10 patents)

silverMedal Steve Pakola (10 out of 10 patents)

bronzeMedal Jean-Marie Stassen (4 out of 6 patents)

4.  Peter Carmeliet (3 out of 21 patents)

5.  Richard Reinier Zwaal (3 out of 4 patents)

6.  Désiré Collen (3 out of 10 patents)

7.  Ingeborg Stalmans (2 out of 2 patents)

8.  Luc Schoonjans (2 out of 3 patents)

9.  Claudia Fromond (1 out of 6 patents)

10.  Hoa Thu Ngo (1 out of 1 patent)

11.  Sofie Notebaert (1 out of 1 patent)

12.  Emmanuel Sneyders (1 out of 1 patent)

13.  Jean Marie Stassen (1 out of 1 patent)

14.  Hans Nicasy (1 out of 1 patent)

15.  Bart Jonckx (1 out of 1 patent)


21 patents:

1. 9884910 - Anti-PDGF-C antibodies (2018-02-06),
2. 9770494 - Pharmacological vitreolysis (2017-09-26),
3. 9644196 - Plasminogen and plasmin variants (2017-05-09),
4. 9445078 - Stereo-vision system (2016-09-13),
5. 9226953 - Variants of plasminogen and plasmin (2016-01-05),
6. 9186394 - Pharmacological vitreolysis (2015-11-17),
7. 9089552 - Improving trabeculectomy outcome by administering an anti-placental growth factor antibody (2015-07-28),
8. 9085617 - Anti-angiogenic therapy (2015-07-21),
9. 8993323 - Compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability and for the culture of adult stem cells (2015-03-31),
10. 8920794 - Method for treating filtration failure after trabeculectomy surgery (2014-12-30),
11. 8834869 - Pharmacological vitreolysis (2014-09-16),
12. 8758748 - Anti-angiogenic therapy (2014-06-24),
13. 8747842 - Pharmacological vitreolysis (2014-06-10),
14. 8697444 - Compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability and for the culture of adult stem cells (2014-04-15),
15. 8460655 - Pharmacological vitreolysis (2013-06-11),
Company Overview
Thrombogenics NV is a biotechnology company based in Leuven, Belgium, specializing in the development of innovative therapies for eye diseases and other medical conditions. The company focuses on advancing treatments that target vascular health, particularly in the field of retinal diseases. Thrombogenics is committed to research and development, leveraging cutting-edge technology to create effective solutions that improve patient outcomes and address unmet medical needs in the healthcare sector.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

21 Patents

#9 in Leuven

#155 in Belgium

#30,018 in the World

Leuven, BE
Leuven, Belgium

Thrombogenics Nv

Forward Citations = 82

16 inventors:

goldMedal Marc De Smet (10 out of 10 patents)

silverMedal Steve Pakola (10 out of 10 patents)

bronzeMedal Jean-Marie Stassen (4 out of 6 patents)

4.  Peter Carmeliet (3 out of 21 patents)

5.  Richard Reinier Zwaal (3 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Thrombogenics Nv. Retrieved from https://idiyas.com/company/thrombogenics-nv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…